On June 27, 2019 Calithera Biosciences reported that Cancer cells are known to rely on glycolysis as an energy source (Press release, Calithera Biosciences, JUN 27, 2019, View Source [SID1234537318]). CB-839 (Calithera Biosciences) inhibits the glutaminase enzyme, reducing the ability of cancer cells to utilize glutamine in this biochemical pathway, thereby reducing cell proliferation and tumor growth.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
If approved, CB-839 will be the first glutaminase inhibitor approved for the treatment of renal cell carcinoma (RCC). This novel mechanism of action could place CB-839 in a unique position in the RCC market and provide physicians with an alternative treatment option.
CB-839 is being investigated in combination with either Afinitor (everolimus; Novartis) or Cabometyx (cabozantinib; Exelixis/Ipsen/Takeda) for previously treated advanced RCC patients, suggesting it will not compete with the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) therapies being developed for first-line use.
CB-839 is being developed by Calithera Biosciences, a company that is yet to bring an oncology product to market. Due to Calithera’s limited geographic scope, the author expects the company to look for partners to market CB-839 in Japan and the EU.
Key Topics Covered:
OVERVIEW
Drug Overview
Product Profiles
CB-839 : Renal cell carcinoma (RCC)
LIST OF FIGURES
CB-839 for RCC – SWOT analysis
The authors drug assessment summary of CB-839 for RCC
CB-839 sales for RCC in the US, 2017-26
LIST OF TABLES
CB-839 drug profile
CB-839 Phase II trials in RCC
CB-839 sales for RCC in the US ($m), 2017-26
For more information about this report visit View Source